Shares of 23andMe Holding Co. (ME) are up over 20% at $1.33 in premarket trading Friday, following FDA clearance to expand its existing BRCA1/BRCA2 Genetic Health Risk Report.
A Genetic Health Risk report indicates the presence of specific genetic variants linked to an increased likelihood of developing a disease although it does not describe a person's overall risk of developing the disease.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.